Home
About Us
Group Introduction
Founder Introduction
Global Cooperation
Nanolattix Biotechnology
Company Profile
Development History
Research Layout
Nanolattix Health
Extraction Platform
Cosmetics
Machine
Food Brand
Disinfection
Oem/Odm
News
Company News
Industry News
Contact Us
简体中文
English
Company profile
Development history
Research layout
2024.12
Nanolattix T320 Cancer Drug Successfully Receives U.S. FDA Clinical Approval
2024.11
Nanolattix's Innovative Drug T320 Receives Clinical Trial Approval from Australia's TGA
2024.9
Nanolattix Submits Dual IND Applications for Cancer Drug T320 in China and the U.S
2024.5
U.S. FDA Grants Orphan Drug Designation to Nanolattix T320 for Pancreatic Cancer Treatment
2024.4
Nanolattix T320-ADC Successfully Selected and Signed as a 'Major Special Project' in Shanxi Province!
2023.12
Nanolattix Completes Tens of Millions in Series A Financing
